Report Company Directory

VIEWTRAN GROUP INC

VIFAG 2002 SIMCAV SA

Vifor Pharma AG

Vifor Pharma AG

• Monthly LMI Update Independent Investment Research by Independent Investment Research
• Feasibility Study Results in December to be a Catalyst for this Junior by Fundamental Research
• Espresso | Galenica | Reduce | Reduce, target price under review by Kepler Cheuvreux
• Espresso | Galenica | Reduce | Santé IPO confirmed by Kepler Cheuvreux
• Espresso | Galenica | Reduce | Iron estimates up, Veltassa cut by Kepler Cheuvreux
• Espresso | Galenica | Reduce | Veltassa miss by Kepler Cheuvreux
• Espresso | Galenica | Reduce | Sprint stake done by Kepler Cheuvreux
• Espresso | Galenica | Reduce | IPO range set at CHF1.55-1.95bn market cap by Kepler Cheuvreux
• Espresso | Galenica | Reduce | Estimates adjusted for Milestone 2020 by Kepler Cheuvreux
• Q&A Report | Galenica | Reduce | What will shareholders face post-IPO? by Kepler Cheuvreux

Vifor Pharma AG

• ODDO : Defensive growth sectors by Oddo BHF
• ODDO : Defensive growth sectors by Oddo BHF
• Vifor Pharma AG by CFRA Research
• Vifor Pharma to propose Dr Alexandre LeBeaut as Board member by BusinessWire
• VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR) by BusinessWire
• Vifor Pharma supports Iron Deficiency Day 2020 to highlight global impact on health and gender inequality by BusinessWire
• VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa® agreement by BusinessWire
• Full Results From AFFIRM-AHF Study Show Ferinject® Significantly Reduces Hospitalizations After Acute Heart Failure in Patients With Iron Deficiency by BusinessWire
• Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications by BusinessWire
• VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan  by BusinessWire